Please share your phone number so we can contact you to learn about your health complaint.
Keytruda (Pembrolizumab) is one of the most advanced and widely recognized cancer treatments available today. As part of the new generation of immunotherapy drugs, Keytruda has transformed oncology care worldwide and given hope to thousands of patients, including many in Egypt and the MENA region.
Keytruda is an immune checkpoint inhibitor that belongs to the class of PD-1 inhibitors. The drug works by blocking the PD-1 protein on immune cells, which cancer cells normally use to escape detection. By stopping this “immune evasion,” Keytruda activates the body’s immune system to identify and destroy cancer cells.
This innovative approach has made Keytruda a cornerstone in the treatment of multiple advanced cancers.
Keytruda is approved and widely used in the treatment of:
Non-small cell lung cancer (NSCLC)
Advanced melanoma (skin cancer)
Head and neck cancers
Kidney cancer
Bladder cancer
Colorectal cancer (with specific biomarkers)
Certain types of lymphoma
Eligibility for Keytruda treatment is often determined by tests such as PD-L1 expression or other genetic markers, ensuring that the right patients benefit most.
Keytruda is administered as an intravenous (IV) infusion in a hospital or cancer center.
The infusion typically takes around 30 minutes.
Depending on the treatment plan, patients usually receive a dose every 3 or 6 weeks.
Because Keytruda stimulates the immune system, it may cause immune-related side effects, such as:
Fatigue and weakness
Loss of appetite
Rash or itching
Cough or shortness of breath
Thyroid or liver function changes
Diarrhea or colitis
Close monitoring by an oncologist is essential during Keytruda treatment to manage side effects effectively.
Keytruda may not be suitable for:
Patients with severe allergies to its components
Patients who have undergone organ transplantation
Those on strong immunosuppressive therapy
Keytruda is manufactured by Merck & Co., a leading global pharmaceutical company known for its innovation and reliability in oncology care.
In Egypt, Keytruda is available through specialized oncology centers. However, due to its high cost and the complexity of cancer care, patients often need professional coordination and guidance.
At Macrocare, we support patients by:
Connecting you with top oncologists in Egypt and abroad
Organizing treatment plans that include Keytruda
Providing end-to-end medical tourism services: travel, hospital admission, and aftercare
Ensuring patients and families have full support throughout their cancer journey
Keytruda (Pembrolizumab) is more than just a drug – it represents a breakthrough in how we fight cancer. While its price remains high, the effectiveness of Keytruda in improving survival and treatment outcomes has made it one of the most in-demand therapies worldwide.
With Macrocare, patients in Egypt and beyond can access world-class oncology care, including Keytruda treatment, supported by a team dedicated to guiding them every step of the way.
Contact Macrocare today to learn more about how Keytruda could be part of your personalized cancer treatment plan.